The direct oral anticoagulants (DOACs), now including dabigatran, apixaban and
rivaroxaban, have given clinicians alternative options to low molecular weight heparins …

The new direct oral anticoagulants (DOACS) dabigatran, rivaroxaban, apixaban and
edoxaban provide alternatives to warfarin for treatment and prevention of atrial fibrillation …

Anticoagulant therapy monitoring provides the largest volume of work in most routine
coagulation laboratories. 1–3 Currently, the main anticoagulant armamentarium comprises …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

Context Rivaroxaban is a new oral anticoagulant that functions as a direct anti-Xa inhibitor.
Although routine monitoring is not required, measurement of plasma concentrations may be …

Background Clinical situations occur where expedient assessment of the anticoagulant
activity of the direct factor Xa (FXa) inhibitors is required. Although quantitative anti‐FXa …

This review provides an update on laboratory testing and monitoring for existing and
emerging anticoagulants, starting with an overview of haemostasis and the routine …

Why is the need for these tests so urgent? Quantification of plasma concentrations of the
DOACs is critical when assessing their potential contribution to serious bleeding, when …

Background During treatment with direct oral anticoagulants (DOAC), coagulation
assessment is required before thrombolysis, surgery, and if anticoagulation reversal is …

The introduction of several oral direct anticoagulants within the past 2–3 years has
dramatically changed clinical practice and has also impacted on utilization and …